Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study.

BMC Cancer · 2010 · PMC2927999 · PMID 20569446

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In our analysis of OED group, they did not show a significant PFS difference between patients with chemotherapy plus rituximab and those with chemotherapy alone, but only showed a trend of improved OS for patients treated with chemotherapy plus rituximab.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.